1. Home
  2. PRAX vs TWFG Comparison

PRAX vs TWFG Comparison

Compare PRAX & TWFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRAX
  • TWFG
  • Stock Information
  • Founded
  • PRAX 2015
  • TWFG 2001
  • Country
  • PRAX United States
  • TWFG United States
  • Employees
  • PRAX N/A
  • TWFG N/A
  • Industry
  • PRAX Biotechnology: Pharmaceutical Preparations
  • TWFG
  • Sector
  • PRAX Health Care
  • TWFG
  • Exchange
  • PRAX Nasdaq
  • TWFG NYSE
  • Market Cap
  • PRAX 599.7M
  • TWFG 530.3M
  • IPO Year
  • PRAX 2020
  • TWFG 2024
  • Fundamental
  • Price
  • PRAX $46.32
  • TWFG $34.51
  • Analyst Decision
  • PRAX Strong Buy
  • TWFG Buy
  • Analyst Count
  • PRAX 11
  • TWFG 8
  • Target Price
  • PRAX $114.73
  • TWFG $33.71
  • AVG Volume (30 Days)
  • PRAX 299.7K
  • TWFG 113.8K
  • Earning Date
  • PRAX 08-12-2025
  • TWFG 05-13-2025
  • Dividend Yield
  • PRAX N/A
  • TWFG N/A
  • EPS Growth
  • PRAX N/A
  • TWFG N/A
  • EPS
  • PRAX N/A
  • TWFG N/A
  • Revenue
  • PRAX $8,122,000.00
  • TWFG $211,440,000.00
  • Revenue This Year
  • PRAX N/A
  • TWFG $23.90
  • Revenue Next Year
  • PRAX $6,358.50
  • TWFG $22.60
  • P/E Ratio
  • PRAX N/A
  • TWFG N/A
  • Revenue Growth
  • PRAX 270.02
  • TWFG 18.57
  • 52 Week Low
  • PRAX $26.70
  • TWFG $21.31
  • 52 Week High
  • PRAX $91.83
  • TWFG $36.85
  • Technical
  • Relative Strength Index (RSI)
  • PRAX 63.87
  • TWFG N/A
  • Support Level
  • PRAX $40.93
  • TWFG N/A
  • Resistance Level
  • PRAX $44.40
  • TWFG N/A
  • Average True Range (ATR)
  • PRAX 2.26
  • TWFG 0.00
  • MACD
  • PRAX -0.08
  • TWFG 0.00
  • Stochastic Oscillator
  • PRAX 95.12
  • TWFG 0.00

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

About TWFG TWFG INC

TWFG Inc is a independent distribution platform for personal and commercial insurance in the United States. It offers all lines of insurance, multiple distribution contract options, M&A services, proprietary virtual assistants, proprietary technology, proprietary premium financing, unlimited continuing education, recognition programs, co-op funding, marketing support and overall lower costs to operate.

Share on Social Networks: